Gut Fibroblasts Drive Epithelial Cell Death in IBD via Lipid Enzyme ACSL4
Fibroblast lipid metabolism reprograms intestinal epithelial cells toward ferroptosis in IBD, pointing to ACSL4 as a precise therapeutic target.
Summary
Researchers at the University of Michigan discovered that intestinal fibroblasts in inflammatory bowel disease (IBD) overexpress ACSL4, an enzyme that reprograms lipid metabolism and sensitizes neighboring epithelial cells to ferroptosis—an iron-dependent form of programmed cell death driven by lipid peroxidation. In mouse models of chronic colitis, fibroblast-specific overexpression of ACSL4 worsened epithelial damage and colitis severity, while pharmacological inhibition or genetic deletion of fibroblast ACSL4 provided protection. This heterocellular crosstalk between fibroblasts and epithelial cells reveals a previously unrecognized mechanism of mucosal injury in IBD and suggests that targeting ACSL4 in fibroblasts could offer a more precise antioxidant therapeutic strategy than broad ROS suppression.
Detailed Summary
Inflammatory bowel disease (IBD) is characterized by chronically elevated reactive oxygen species (ROS) and ongoing intestinal epithelial cell death, yet broad antioxidant therapies have consistently underperformed in clinical trials. This study, published in Nature Metabolism in July 2025, proposes a refined mechanistic explanation: lipid peroxidation-driven ferroptosis, orchestrated not within epithelial cells themselves but by adjacent intestinal fibroblasts, is a central driver of mucosal injury in IBD.
The research team identified that acyl-CoA synthetase long-chain family member 4 (ACSL4)—an enzyme that channels polyunsaturated fatty acids into phospholipids, priming membranes for oxidative damage—is markedly overexpressed in fibroblasts within IBD patient tissues and mouse models of chronic colitis. This fibroblast-specific upregulation reprograms the local lipid environment through heterocellular crosstalk, rendering neighboring intestinal epithelial cells (IECs) hypersensitive to ferroptotic death. Critically, the fibroblast lipid signal, not the epithelial cell's own ACSL4 activity, determines IEC vulnerability.
In gain-of-function mouse models, fibroblast-targeted overexpression of ACSL4 amplified intestinal epithelial ferroptosis and significantly worsened colitis phenotypes. Conversely, fibroblast-specific genetic deletion of ACSL4 or pharmacological inhibition of ACSL4 activity attenuated colitis severity, reduced ferroptotic epithelial cell death, and improved mucosal integrity. These findings establish a clear causal role for fibroblast ACSL4 in IBD pathophysiology.
The mechanistic insight—that stromal fibroblasts act as upstream regulators of epithelial cell death mode—represents a conceptual advance in understanding IBD. Rather than each cell type independently responding to oxidative stress, this work demonstrates a coordinated, intercellular lipid signaling axis. This may explain why epithelial-centric antioxidant strategies have had limited efficacy: the primary metabolic insult originates in the stroma.
From a translational standpoint, fibroblast ACSL4 emerges as an actionable therapeutic target. Pharmacological ACSL4 inhibitors already exist and could be repositioned for IBD with the potential for cell-type selectivity. The study also raises important questions about whether similar fibroblast-to-epithelium ferroptotic signaling operates in other inflammatory or fibrotic gastrointestinal conditions, and whether biomarkers of fibroblast ACSL4 activity could stratify IBD patients most likely to benefit from ferroptosis-targeted therapies.
Key Findings
- ACSL4 is overexpressed specifically in intestinal fibroblasts—not epithelial cells—in IBD patients and colitis mouse models.
- Fibroblast ACSL4 reprograms lipid metabolism and sensitizes neighboring epithelial cells to ferroptotic cell death via heterocellular crosstalk.
- Fibroblast-specific ACSL4 overexpression worsened chronic colitis and increased epithelial ferroptosis in mouse models.
- Genetic deletion or pharmacological inhibition of fibroblast ACSL4 ameliorated colitis severity and reduced epithelial cell death.
- Targeting stromal ACSL4, not broad ROS suppression, may offer a more precise IBD therapeutic strategy.
Methodology
The study combined analysis of IBD patient tissue with genetic mouse models featuring fibroblast-specific ACSL4 overexpression or deletion in chronic colitis. Pharmacological ACSL4 inhibition was also tested in vivo, alongside co-culture and lipidomic approaches to establish the fibroblast-to-epithelial crosstalk mechanism.
Study Limitations
The study is based on mouse colitis models and human tissue correlations; direct causal evidence in human IBD patients is lacking. The precise lipid mediators transferred from fibroblasts to epithelial cells and the exact signaling mechanisms of crosstalk require further elucidation. Long-term safety and specificity of fibroblast-targeted ACSL4 inhibition have not yet been assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.